Biochemical pharmacologyHumansVemurafenibMelanomaPhospholipase DDrug Resistance
Phospholipase D2 regulation by transcription factor FOXA1 promotes the drug resistance of vemurafenib in melanoma cells.
Jun Liu, Lingjun Li, Cheng Wang, Chenjie Liu, Jinkang He, Pengcheng Ma, Hongyang Li
Published: 202510.1016/j.bcp.2025.117434
Abstract
The clinical effectiveness of vemurafenib that targets BRAF V600E mutation in patients with melanoma had been recognized. However, the drug resistance severely hampers the clinical application of vemurafenib. We combined metabolomics and transcriptom…
Preview only. Read the full abstract at the source